The role of rapid diagnostics and collaboration in antibiotic stewardship
Panelists discuss the pivotal role of microbiology laboratories and rapid diagnostic technologies in managing multidrug-resistant infections, highlighting their impact on timely treatment, antibiotic stewardship, and the need for interdisciplinary collaboration to effectively interpret and act on resistance data.
In this portion of the discussion, the panel shifts focus to the critical role microbiology laboratories play in managing multidrug-resistant infections, particularly through diagnostic testing. A microbiologist explains how traditional susceptibility testing is no longer sufficient in the era of global travel and evolving resistance mechanisms. Rapid diagnostics now enable earlier and more accurate pathogen identification, essential for initiating appropriate treatment and controlling infection spread. These technologies improve clinical outcomes and support antibiotic stewardship by enabling faster de-escalation from broad-spectrum therapies.
The panelists emphasize how molecular diagnostics—such as multiplex polymerase chain reaction panels and lateral flow assays—have transformed the detection of resistance genes like KPC and NDM, even before susceptibility results are finalized. While these technologies are increasingly adopted in larger hospitals, challenges remain in widespread implementation. Barriers include high costs, limited reimbursement, and staff shortages, particularly in rural and under-resourced settings. Despite these obstacles, rapid diagnostic tools contribute to shorter hospital stays, lower health care costs, and better surveillance for public health, which is crucial as antimicrobial resistance continues to rise globally.
Finally, the speakers underline the importance of interdisciplinary collaboration between microbiologists, clinicians, pharmacists, and infection control teams. Rapid diagnostics can only be effective if the results are properly interpreted and translated into treatment decisions. Education and communication are key, especially for clinicians unfamiliar with resistance gene terminology like VIM, OXA, or IMP. Stewardship teams often serve as the bridge, interpreting lab data and guiding therapy. This collaborative model ensures that advanced diagnostics detect resistance faster and lead to meaningful changes in patient care.
Newsletter
Stay ahead of emerging infectious disease threats with expert insights and breaking research. Subscribe now to get updates delivered straight to your inbox.
